AstraZeneca Fails to Block Biosimilar of Blockbuster Soliris (1)

AstraZeneca Plc unit Alexion Pharmaceuticals Inc. can’t block a biosimilar version of Soliris for the duration of its patent-infringement lawsuit against a Samsung Biologics Co. subsidiary over the $500,000-per-patient treatment, a federal judge ruled.

Alexion sued Samsung Bioepis Co. on Jan. 3 alleging its proposed biosimilar, called SB12, infringes six patents for the blockbuster drug, used to treat rare blood disorders and nerve diseases. Judge Gregory B. Williams on Monday denied Alexion’s Feb. 12 preliminary injunction motion in a sealed order, according to a docket entry in the US District Court for the District of Delaware.

• Williams also canceled a ...